SCI Pharmtech Inc (4119) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SCI Pharmtech Inc (4119) has a cash flow conversion efficiency ratio of 0.007x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$36.89 Million ≈ $1.16 Million USD) by net assets (NT$5.41 Billion ≈ $170.46 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Review 4119 FCF to total liabilities ratio to assess the company's free cash flow relative to its total liabilities.
SCI Pharmtech Inc - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how SCI Pharmtech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see 4119 company net worth for the company's overall valuation and market capitalisation.
SCI Pharmtech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SCI Pharmtech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Creotech Quantum SA
WAR:CRQ
|
N/A |
|
A Plus Asset Advisor Co Ltd
KO:244920
|
0.048x |
|
Sporting Clube de Portugal - Futebol SAD
LS:SCP
|
-0.488x |
|
Bell Equipment Limited
JSE:BEL
|
0.183x |
|
Acme Electronics
TWO:8121
|
0.015x |
|
Vertiseit AB Series B
ST:VERT-B
|
0.046x |
|
Macpower CNC Machines Limited
NSE:MACPOWER
|
0.005x |
|
Staude Capital Global Value Fund Ltd
AU:GVF
|
-0.035x |
Annual Cash Flow Conversion Efficiency for SCI Pharmtech Inc (2002–2025)
The table below shows the annual cash flow conversion efficiency of SCI Pharmtech Inc from 2002 to 2025. View 4119 live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$5.39 Billion ≈ $169.96 Million |
NT$220.32 Million ≈ $6.94 Million |
0.041x | -74.01% |
| 2024-12-31 | NT$5.48 Billion ≈ $172.55 Million |
NT$860.52 Million ≈ $27.11 Million |
0.157x | +271.37% |
| 2023-12-31 | NT$5.10 Billion ≈ $160.68 Million |
NT$215.77 Million ≈ $6.80 Million |
0.042x | -48.23% |
| 2022-12-31 | NT$3.63 Billion ≈ $114.34 Million |
NT$296.56 Million ≈ $9.34 Million |
0.082x | -3.19% |
| 2021-12-31 | NT$3.32 Billion ≈ $104.62 Million |
NT$280.28 Million ≈ $8.83 Million |
0.084x | -71.14% |
| 2020-12-31 | NT$3.32 Billion ≈ $104.67 Million |
NT$971.53 Million ≈ $30.61 Million |
0.292x | +28.36% |
| 2019-12-31 | NT$3.47 Billion ≈ $109.47 Million |
NT$791.60 Million ≈ $24.94 Million |
0.228x | +52.31% |
| 2018-12-31 | NT$3.21 Billion ≈ $101.14 Million |
NT$480.18 Million ≈ $15.13 Million |
0.150x | +55.59% |
| 2017-12-31 | NT$2.93 Billion ≈ $92.30 Million |
NT$281.65 Million ≈ $8.87 Million |
0.096x | -41.20% |
| 2016-12-31 | NT$3.07 Billion ≈ $96.75 Million |
NT$502.11 Million ≈ $15.82 Million |
0.164x | -31.91% |
| 2015-12-31 | NT$2.76 Billion ≈ $87.02 Million |
NT$663.24 Million ≈ $20.90 Million |
0.240x | +49.00% |
| 2014-12-31 | NT$2.23 Billion ≈ $70.14 Million |
NT$358.77 Million ≈ $11.30 Million |
0.161x | +39.69% |
| 2013-12-31 | NT$2.07 Billion ≈ $65.15 Million |
NT$238.57 Million ≈ $7.52 Million |
0.115x | -62.24% |
| 2012-12-31 | NT$1.26 Billion ≈ $39.76 Million |
NT$385.57 Million ≈ $12.15 Million |
0.306x | +38.51% |
| 2011-12-31 | NT$1.13 Billion ≈ $35.64 Million |
NT$249.55 Million ≈ $7.86 Million |
0.221x | +13.97% |
| 2010-12-31 | NT$1.13 Billion ≈ $35.64 Million |
NT$218.96 Million ≈ $6.90 Million |
0.194x | -36.62% |
| 2009-12-31 | NT$1.04 Billion ≈ $32.70 Million |
NT$316.96 Million ≈ $9.99 Million |
0.305x | +17.35% |
| 2008-12-31 | NT$942.51 Million ≈ $29.69 Million |
NT$245.29 Million ≈ $7.73 Million |
0.260x | +37.66% |
| 2007-12-31 | NT$886.14 Million ≈ $27.92 Million |
NT$167.53 Million ≈ $5.28 Million |
0.189x | +11.61% |
| 2006-12-31 | NT$777.01 Million ≈ $24.48 Million |
NT$131.62 Million ≈ $4.15 Million |
0.169x | +69.60% |
| 2004-12-31 | NT$767.10 Million ≈ $24.17 Million |
NT$76.61 Million ≈ $2.41 Million |
0.100x | -63.76% |
| 2003-12-31 | NT$750.63 Million ≈ $23.65 Million |
NT$206.86 Million ≈ $6.52 Million |
0.276x | +40.49% |
| 2002-12-31 | NT$546.06 Million ≈ $17.20 Million |
NT$107.12 Million ≈ $3.37 Million |
0.196x | -- |
About SCI Pharmtech Inc
SCI Pharmtech, Inc. engages in the research and development, manufacture, and sale of active pharmaceutical ingredients, intermediates, and specialty chemicals. The company offers active pharmaceutical ingredients, including adenine, articaine HCl, atomoxetine HCl, bisoprolol hemifumarate, brinzolamide, buprenorphine and buprenorphine HCl, cannabidol, divalproex sodium, duloxetine HCl, hydroxychl… Read more